ArticleAmerican journal of translational research2026
Fetal echocardiography combined with serum biomarkers for early diagnosis of congenital heart disease and birth defect risk prediction.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the significance of fetal echocardiography in the early diagnosis of congenital heart disease (CHD) and its use as an early warning system for birth defects when combined with maternal serum biomarkers.
methodsA retrospective study was conducted at the Maternal & Child Care Center of Qinhuangdao between 2022 and 2025. A total of 260 pregnant women with suspected fetal cardiac abnormalities who underwent prenatal examinations were included. Based on postnatal diagnosis, participants were divided into a CHD group (n=41) and a non-CHD group (n=219). Diagnostic efficacy was compared between the four-chamber view with cranial deviation (FCV-CD) alone and FCV-CD combined with sequential segmental analysis (SSA). Maternal serum β-human chorionic gonadotropin (β-hCG) and N-terminal pro-B-type natriuretic peptide (N-proBNP) levels were analyzed, as well as their correlations with CHD. The predictive performance of single diagnostic strategy and combined strategies (ultrasound + biomarkers) was also evaluated.
resultsCombining FCV-CD with SSA substantially improved CHD detection, attaining a significantly higher sensitivity. Compared to the non-CHD group, the CHD group showed notably lower maternal β-hCG levels and higher N-proBNP levels (both P<0.001). Logistic regression analysis confirmed significant correlations between β-hCG, N-proBNP, and CHD. FCV-CD combined with SSA demonstrated excellent diagnostic precision, and further integration with biomarkers increased specificity to 92.24%.
conclusionsThe integration of FCV-CD and SSA significantly improved the diagnostic efficacy of fetal echocardiography for CHD. Incorporating maternal β-hCG and N-proBNP further improved diagnostic specificity, providing an effective early warning system for congenital heart defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.